INTRODUCTION
Vitamin A (retinol) and its related analogs, collectively called retinoids, play a pivotal role in cell growth and differentiation (for review, see (Gudas et al., 1994) . In the respiratory system, retinoic acid (RA) 1 , the natural metabolite of vitamin A, controls the development and maintenance of differentiated mucociliary epithelial cells. It has been well documented that RA is essential for induction and maintenance of normal mucociliary airway epithelium (McDowell et al., 1984a; McDowell et al., 1984b) . RA deficiency causes squamous metaplasia, and supplementation with RA restores the normal mucous cell phenotype in cultured primary bronchial epithelial cells (Koo et al., 1999) . However, the early effect of RA on mucous cell differentiation of bronchial epithelia is largely unknown.
It has been well documented that the effects of RA at the genomic level are mediated mainly through heterodimerized forms of retinoid receptors, RARs and RXRs, which recognize expression of their target genes through the RA response element (A/G)G(G/T)TCA upon binding of RA and activate gene expression (Giguere, 1994; Mangelsdorf and Evans, 1995; Chambon, 1996) . Recent data showed, however, that RA action could be diversified to other cellular signaling pathways, the so-called nongenomic action of RA. For example, RA has been shown to modulate PKC activity by binding directly to PKC. RA binds directly to the C2-domain of PKCα (Ochoa et al., 2002) , as determined by structural analysis of the cocrystalized C2-domain of PKC with RA. In addition, RA binding to the phosphatidyl serine binding site of PKCα was determined by photoaffinity labeling assay (Radominska-Pandya et al., 2000) . It has also been shown that retinol and its metabolites bind to the cysteine-rich region of the regulatory domain of -3 -several PKC isoforms, including α, δ, ζ, and μ (Hoyos et al., 2000; Imam et al., 2001) .
Therefore, we hypothesized that these diversified actions of RA may play an important role, particularly, in triggering early events of the differentiation of bronchial epithelia, where RA receptors are less abundant to transmit RA action.
The transcription factor CREB plays important roles in controlling cell growth, survival, and cell cycle progression and in determining the fate of many cell types, including vascular smooth muscle cells (Klemm et al., 2001) , adipocytes (Reusch et al., 2000) , thyrocytes (Nguyen et al., 2000) , Sertoli cells (Scobey et al., 2001) , and neurons (Sung et al., 2001) . Recently, it has been also demonstrated that CREB promotes abnormal proliferation and survival of myeloid cells and was implicated as a proto-oncogene in myeloid transformation (Shankar et al., 2005) .
CREB is a member of the closely related CREB/CREM/ATF family of transcription factors, recognize CRE, 5'-TGACGTCA-3', in the transcription-regulatory regions of its target genes (for review, see (Mayr and Montminy, 2001) . Recently, genome-wide analysis of the regulatory regions of the CREB revealed numerous novel CREB target genes (Impey et al., 2004) . CREB was initially identified as a substrate for protein kinase A (PKA) and has been shown to be activated in response to various extracellular stimuli (e.g., hormones, growth factors, cytokines, and stress signals, (for review, see (Johannessen et al., 2004) via diverse signaling molecules, including PKA (Gonzalez et al., 1989; Montminy et al., 1990) , PKC (Yamamoto et al., 1988) , RSK (Xing et al., 1996) , mitogen-and stressactivated protein kinase 1 (Deak et al., 1998) , ERK1/2 (Fix et al., 2004) , mitogen-activated protein kinase (MAPK) -activated protein 2 kinase (Tan et al., 1996) , Akt (Du and Montminy, 1998) , and calcium-and calmodulin-dependent protein kinases II (Sun et al., 1994) and IV (Matthews et al., 1994) . These kinases phosphorylate CREB at serine 133 -4 -residue (Yamamoto et al., 1988; Gonzalez et al., 1989) , which is required for the recruitment of CREB binding protein to induce CREB-mediated transactivation of transcription.
In this study, we sought to elucidate the nonclassical mechanisms of RA activation of the transcription factor CREB in primary human bronchial epithelial cells. We found that RA rapidly activates CREB in a dose-and time-dependent manner and also activates ERK1/2 and RSK, a major upstream kinase of CREB. Rapid and strong activation of ERK1/2 and RSK is required for CREB activation. Our data further demonstrate that RA stimulation of the CREB signaling cascades does not appear to involve nuclear RA receptors.
MATERIALS AND METHODS

Cell Cultures and Chemicals.
NHTBE cells (Clonetics, San Diego, CA) were cultured by air-liquid interface method as described previously (Gray et al., 1996; Koo et al., 1999; Kolodziejski et al., 2002) . Briefly, the second passage NHTBE cells were seeded at a density of 1 × 10 5 cells onto 24-mm semipermeable membrane inserts (Transwell-Clear; Corning, Inc., Acton, MA) and grown in serum-free growth factor and hormone-supplemented culture medium. chemicals including Ro 31-8220, GF 109203X, Rottlerin, SP600125, SB203580, Y27632, U0126, 2′,5′-Dideoxyadenosine, and U73122 were purchased from Calbiochem (San Diego, CA) and were dissolved in DMSO .
Western Blot Analysis and Antibodies.
Western blot analysis was performed as previously described (Song et al., 2003) .
Whole-cell extracts were prepared using 2x sodium dodecyl sulfate (SDS) Laemmli lysis buffer. Cytosolic and nuclear fractions were prepared according to the manufacturer's instructions (Nuclear and Cytoplasmic Extraction Reagent; Pierce, Rockford, IL Heights, IL).
Electrophoretic Mobility Shift Assays
-6 -EMSA were performed as described elsewhere (Gray et al., 2001; Aggarwal et al., 2004) with necessary modifications. reporter lysis buffer (Promega, Madison, WI), and luciferase reporter and β-gal activities were determined by using a luminometer (Lumant LB 9507, EG & Berthold, Germany).
RNA Interference
SMARTpool-sequenced small-interference RNA (siRNA) targeting human RSK1
RXRα (Accession #NM_002957), and non-specific control pool (siRNA negative control) (Dharmacon RNA Technologies, Lafayette, CO) were diluted and stored according to the manufacturer's instructions. The siRNA SMARTpool used in this study contained four pooled RNA duplexes with "UU" 3'-overhangs and 5'-phosphate on the antisense strand. A mixture of several siRNAs ensured effective deletion of the target gene in the cell. H1734 cells at 50% confluence or NHTBE cells at 60% to 70% confluence were transfected with a final concentration of 100 nM SMARTpool siRNA or non-specific control pool by using the siIMPORTER siRNA transfection reagent (Upstate Biotechnology) according to the manufacturer's instructions. The cells were treated with RA for 30 min or 24 h after 72 h of transfection, when target protein levels had been reduced by 70% to 80% as assessed by
Western blot analysis.
-9 -
Reverse Transcription (RT)-PCR
Total RNA was extracted using RNeasy mini-kits (Qiagen, Valencia, CA). The reverse transcription reaction was performed using 1 μg of total RNA that was reverse-transcribed into cDNA using a random hexamer primer (GeneAmp RNA PCR Core kit; Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. PCR conditions were an initial 95°C for 5 min, followed by 30 cycles of 95°C, 55°C, and 68°C for 30 s each. PCR for β-actin (Ambion, Austin, TX) was done as an internal control. Primer sequences were as follows: RARβ sense, AGCCTACGTGCCAAAAAAGG-3', and
antisense, 5'-TCTAGGTGTGGAGGCAAATGG-3'; and CREB sense, 5'-ACCATGGAATCTGGAGCCGAGAAC-3', and antisense; 5'-CTGTAGGAAGGCCTCCTTGAAAGA-3'. PCR products were then separated in a 2%
agarose DNA gel and stained with ethidium bromide.
RESULTS
CREB Is Activated by RA in a Time-and Dose-Dependent Manner-We used Western blot
analysis to determine the time and dose responsiveness of RA on the activation of CREB.
As shown in Figure 1A , RA induced activation of CREB in a time-dependent manner.
CREB activation was detected as early as 15 min after RA treatment and reached a maximum at 1 h; pCREB remained activated for 4 h thereafter. The levels of CREB remained unchanged. It is unequivocally clear that the RA-induced phosphorylation of CREB occurred in a dose-dependent manner ( Figure 1B ). CREB was activated by as little as 10 nM RA. Forskolin, a known activator of PKA and an upstream activator of CREB,
-1 0 -was used as a positive control to monitor the level of comparable activation of CREB. The levels of CREB remained unchanged.
To determine whether transcriptional activity is involved in the activation of CREB by RA, NHTBE cells grown in RA-deficient medium for 7 days were preincubated with actinomycin D (a general inhibitor of mRNA transcriptional synthesis) for 2 h, followed by incubation with 1 μM RA or vehicle control for 4 h. As shown in Figure 1C , actinomycin D had no effect on RA-induced CREB gene expression. To determine whether new protein synthesis is required for RA action in the CREB pathway, NHTBE cells grown in RAdeficient medium for 7 days were preincubated with cycloheximide (a general inhibitor of protein synthesis) for 2 h, followed by incubation with 1 μM RA or vehicle control for 4 h.
As shown in Figure 1D , CREB expression and phosphorylation remained constant when protein synthesis was blocked. Thus, these results showed that the de novo synthesis of mRNA and protein is not required for the activation of CREB by RA, suggesting that RA's action in the CREB pathway is independent of transcriptional or translational regulation.
RA Induces Activation of Nuclear CREB-It has been reported that CREB is translocated
after activation by calcium in vascular smooth muscle cells (Stevenson et al., 2001) . To determine whether RA-activated CREB translocates from the cytoplasm to the nucleus, we determined the location of CREB and pCREB in nuclear and cytoplasmic fractions isolated from NHTBE cells treated with 1 μM RA for 15, 30, or 60 min. As shown in Figure 1E , the majority of CREB was localized within the nuclear fraction and that RA-activated CREB resided in the nuclear fraction. The activation was maximal within 15 min and continued for another 60 min with no change in the level of CREB in the nuclear fraction ( Figure 1E ). CREB phosphorylation and CREB levels were much weaker in the cytoplasmic fraction Supershift analysis was used to determine whether the retarded band visualized on EMSA in RA-treated cells was indeed due to the binding of CREB to the specific CRE sequence in DNA. As shown in Figure 2C , pCREB and CREB (data not shown) antibodies shifted the band to a higher molecular mass, and addition of 100-fold excess of unlabeled (cold) CRE consensus oligonucleotide caused complete disappearance of the CREB band, showing that the mutant oligonucleotides could not compete for binding. PIS had no effect.
These results suggest that RA activation of CREB indeed results in specific binding to the -1 2 -CRE consensus DNA sequence and that most, if not all, CREB was in a phosphorylated form in the presence of RA, as pCREB almost completely supershifted the retarded band. As shown in Figure 2E , RA increased CRE promoter activity in a dose-dependent manner in the lung cancer cell lines. The increase was 14-fold in H1734 cells at 1 μM RA treatment over that of untreated control, results were consistent with those in NHTBE cells. Further, CRE-promoter activity after RA treatment was 12-fold that in the control ( Figure 2F ). This increase was further enhanced 19-fold by expression of wild-type CREB, whereas RAinduced CRE promoter activity was markedly suppressed by expression of dominant negative mutant forms of CREB, CREB133 and KCREB, in NHTBE cells. These results clearly demonstrate that CRE transactivation by RA is dependent on CREB.
CRE-Dependent Transcriptional
-1 3 -
Role of RAR and RXR in Regulating Phosphorylation of CREB and CRE-dependent
Transactivation by RA-We next determined whether other types of retinoids, such as alltrans RA, 9-cis RA, 13-cis RA, and retinol, also activate CREB in NHTBE cells. CREB was equivalently activated after incubation for 30 min with each of these retinoids ( Figure   3A ). Of particular interest, retinol also activated CREB as soon as 30 min after treatment ( Figure 3B and 3C ) and was maintained for at least 2 h in NHTBE ( Figure 3B ) and H1734 ( Figure 3C ) cells. Thus, it is unequivocally clear from the result that CREB activation by retinoids is not limited to all-trans RA.
To determine whether RAR and RXR are involved in the activation of CREB by RA, NHTBE and H1734 cells were pre-treated with 10 μM Ro 61-8431 (pan-RAR antagonist) or Ro 26-5405 (pan-RXR antagonist) for 1 h and then were incubated with RA for 30 min. Pretreatment with pan-RAR antagonist or pan-RXR antagonist could not block RA-induced CREB phosphorylation in either NHTBE or H1734 cells ( Figure 3D and 3E, respectively). These results indicate that the RAR and RXR receptors were not involved in the RA-induced CREB phosphorylation process. The activities of pan-RAR antagonist and RXR antagonist were verified by measuring the mRNA level of the RAR/RXR-mediated RA target gene RARβ. As shown in Figure 3F and 3G, the expression of RARβ was almost completely blocked by either antagonist. In contrast, the expression of CREB mRNA was not changed by the antagonist treatment. This result demonstrates the efficiency of the antagonist in inhibiting RAR and RXR activity.
To determine whether RAR/RXR is involved in RA-induced CRE-mediated transcription, transient transfection analysis was performed using CRE-luciferase reporter.
As shown in Figure 3H , CRE-luciferase activity was induced by RA and was not affected This result suggests that RA-induced rapid CREB activation does not require RARs/RXRα.
The specificity of the siRNA targeting each receptor was verified by determining protein levels of each receptor using the cell lysates isolated from the siRNA transfected cells (data not shown). Although when the silencing of each receptor reached a maximum after 3 days, residual amounts of RARs and RXRα were still detected. To determine the genetic effect of the residual amounts of RAR/RXR, the expression of RARβ protein was measured. As shown in Figure 4C Figure 5A and 5B shows that a 1 h pre-incubation of these cells with Ro 31-8220, GF 109203X, or U0126 blocked RA induction of CREB activation, while other inhibitors did not block RA induction of CREB activation. Inhibitor treatment alone had no effect on CREB activation.
We further demonstrated that ERK and PKC inhibitors block RA-induced CREB activation in a dose-dependent manner ( Figure 5B) . However, the H-89 (a PKA inhibitor) did not have any effect on the RA activation of CREB. To further determine the role of PKA in the activation, NHTBE cells treated with an inhibitor of adenylate cyclase, an upstream activator of PKA, 2',5'-dideoxyadenosine (2',5'-dd Ado). As shown in Figure 5C , 2'5'-dd Ado did not have any effect on RA-activation of CREB, suggesting the activation is independent of adenylate cyclase and PKA.
-1 6 -whether the MAPK pathway is involved in the RA-dependent signal transduction pathways leading to CREB phosphorylation, we determined the activation status of ERK1/2 and RSK. As illustrated in Figure 6A and 6B, treatment with 1 μM RA caused strong and rapid increases in the amounts of phosphorylated ERK1/2, phosphorylated RSK, and phosphorylated CREB. This increase was observed as soon as 5 min after incubation with RA, was already maximal at 30 min, and was sustained for as long as 2 h ( Figure 6A ). A dose of 1 nM RA also caused increases in the amounts of phosphorylated ERK1/2, phosphorylated RSK, and phosphorylated CREB, but the maximal effect occurred at a dose of 1 μM ( Figure 6B ). In contrast, total levels of ERK1/2, RSK, and CREB as determined with an antibody recognizing the total proteins remained unaltered after RA treatment.
To further determine whether the activation of ERK1/2 and RSK are dependent or not on RAR/RXR, NHTBE and H1734 cells were pretreated with 10 μM pan-RAR antagonist or 10 μM pan-RXR antagonist for 1 h and then were incubated with RA for 30 min.
Pretreatment with pan-RAR antagonist or pan-RXR antagonist could not block RA-induced ERK, RSK, and CREB phosphorylation in either NHTBE or H1734 cells ( Figure 6C and 6D, respectively). Taken together, these results further confirmed that RA-induced CREB activation is independent of RAR and RXR receptor signaling.
RSK1/2 Are Indispensable for Activation of CREB by RA-To further determine whether
RSK is required for the activation of CREB by RA, we used the siRNA approach to silence expression of RSK1 and RSK2. Cotransfection into NHTBE and H1734 cells of a pool of four SMARTpool siRNAs that target both RSK1 and RSK2 resulted in maximal silencing of protein expression 3 days after transfection (data not shown). As shown in Figure 7A -1 7 -and 7B, depletion of RSK1/2 completely abolished RA-induced activation of CREB.
Silencing of RSK1/2, however, did not affect ERK1/2 phosphorylation by RA, because ERK1/2 are upstream kinases of RSK. Transfection of siRSK1/2 or siRNA negative control did not affect CREB activation in control treatment. These results indicate that RSK1/2, an upstream activator of CREB, is indispensable for the activation of CREB by RA.
DISCUSSION
Our findings demonstrate non-genomic receptor-independent RA action resulting in activation of a transcription factor CREB in primary bronchial epithelial cells. This genomic action of RA usually takes hours or even days. However, our work showed that activation of CREB occurred in as little as 15 to 30 min after RA treatment, implying that the time frame is too short to trigger genetic activation through transcription and translation. In fact, de novo synthesis of mRNA and protein was not required for the activation of CREB by RA, suggesting that RA's action in the CREB pathway is independent of genomic transcriptional or translational regulation. The rapid activation of CREB by RA resulted in increased DNA binding of the active CREB to its cognate CRE binding sequence. This result is in consistent with several studies showing increased DNA binding after CREB activation by various stimuli (Zhang et al., 2004) In contrast, there are few reports that activation of CREB did not lead to increased DNA binding activity in vitro (Hagiwara et al., 1993) . Interestingly, most, if not all, of the CREB was present in an active phosphorylated form in the presence of RA, as suggested by the finding that most of the retarded band was supershifted by pCREB antibody.
-1 8 -Our data also suggest that RA activates CREB independently of RAR/RXR, because NHTBE and H1734 cells depleted of RARs/RXRα by means of siRNAs targeting RARα, RARβ, RARγ, and RXRα could still mediate RA-induced activation of CREB.
Furthermore, selective pan-RAR and pan-RXR antagonists did not block RA activation of CREB. Moreover, several retinoids (9-cis-, 13-cis-, and all-trans RA) and even retinol equivalently activated CREB rapidly in as little as 30 min after treatment, suggesting that this action is not limited to all-trans RA. All these results strongly suggest that the action of RA on CREB activation is receptor independent.
The question arises what molecule could mediate this signaling event, if not conventional nuclear retinoid receptors. Our data suggest that PKC is involved in the RAinduced activation of CREB. Several studies provided evidence that RA directly binds to PKC (Radominska-Pandya et al., 2000; Kambhampati et al., 2003; Ochoa et al., 2003) although it is somewhat controversial whether the binding of RA to the PKC activates or inhibits PKC activity. RA activated PKCδ in several cancer cell lines (Kambhampati et al., 2003) or inhibited PKC activity (Radominska-Pandya et al., 2000) . It was also reported to be biphasic, depending on the concentration of RA used, being an activator at a low dose and an inhibitor at a high dose (Lopez-Andreo et al., 2005) . Thus, it is apparent that the effect of RA on PKC is specific to isotypes, cell types, and the concentration of RA. In our primary bronchial epithelial cells, PKC activity was required for CREB activation. ERKs, which are downstream targets of PKC, are involved in the activation of CREB by RA in NHTBE cells. In accordance with our findings, RA has been shown to activate ERK1/2 (Yen et al., 1998; Yen et al., 1999) and p38 MAPK (Alsayed et al., 2001 ).
-1 9 -It was also recently reported that RA induced activation of CREB via ERK, resulting in expression of the c-fos gene, which does not contain RAREs but contains CRE in its promoter (Canon et al., 2004) . However, it is apparent from our data that other MAPK, such as JNK and p38, are not involved in RA activation of CREB. In addition, PKA, one of the well-known CREB kinase, did not participate in RA-mediated CREB phosphorylation.
RA activated RSK is critically required for the activation of CREB, as omitting RSK1/2 by means of siRNAs targeting RSK1/2 completely abolished the activation. It has been shown that RSK is directly phosphorylated by ERK (Sturgill et al., 1988; Frodin and Gammeltoft, 1999) . Most of the CREB is located in the nucleus upon stimulation by RA without obvious translocation of CREB from the cytoplasm to the nucleus. Therefore, activated RSKs must translocate to the nucleus and activate CREB at Ser-133 (Ginty et al., 1994; Xing et al., 1996) . These findings are in agreement with our recent study that showed that interleukin-1β activated CREB through ERK/RSK1/CREB pathway in human airway epithelial cells (Song et al., 2003) . To the best of our knowledge, this is the first report that RSKs are activated by RA in primary bronchial epithelial cells.
Supporting evidence of the activation of transcription factors by RA rather than RAR/RXR has been reported recently. In HL-60, RA increased binding of several transcription factors to their respective consensus sequences (Wang and Yen, 2004) . Some of these transcription factors were shown to be involved in the regulation of the RA target gene, Burkitt's lymphoma receptor, cooperatively with RAR/RXR in HL-60 cells.
However, it was not known whether RAR/RXR are required for the activation of these transcription factors. In our studies CREB activation by RA in bronchial epithelial cells did not require RAR/RXR.
-2 0 -normal bronchial epithelial cells remained unresolved, particularly its significance in the rapid activation of CREB, we speculate that RA may use CREB (or other transcription factors) to induce early RA response genes that do not have a classical RARE in their regulatory region. Alternatively, RA-activated CREB may induce genes to prepare the cells for initiation of a normal differentiation program in which RA receptors are not sufficient.
In fact, we previously observed that expression of RARβ is below detectable level in RAdeficient squamous metaplastic NHTBE cells and that RA increased RARβ expression in these cells 4 h after treatment. RARβ is known to be regulated by CREB through CRE in its promoter (Kruyt et al., 1992) . Since RARβ is also regulated by RAR/RXR through RARE in the promoter of the gene, there is an additional possibility that RA-activated CREB synergistically enhances expression of the genes required for induction of normal mucous cell differentiation. Further extensive studies are required to prove these concepts. After NHTBE cells were treated with 1 μM RA for the indicated times, nuclear (N) and cytoplasmic (C) extracts were prepared and subjected to Western blot analysis using same antibodies (E). NHTBE cells grown in RA-deficient medium on cover glasses for 7 days were subjected to immunocytofluorescence analysis (F and G). cells (B) were cotransfected with RSK1 siRNA (siRSK1), RSK2 siRNA (siRSK2) or nonspecific control pool (NS siRNA). Three days after transfection, the cells were incubated with and also without 1 μM RA for 1 h, and then equal amounts of whole-cell lysates were subjected to Western blot using antibodies against using indicated antibodies. Equal loading was confirmed by stripping the blot and reprobing it for β-actin antibody. All figures are representative of three independent experiments.
